NCT07090525

Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions

Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions-A Prospective Randomized Controlled Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Qingdao Central Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma

Detailed description

This study is a prospective, three-center, randomized, phase II clinical study.

Conditions

• Overall Response Rate

Interventions

Type	Name	Description
DRUG	Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2	Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, repeat use on 21st day if the serous effusion not controlled
DRUG	cisplatin 40mg/m2 intracavity injection	cisplatin 40mg/m2 intracavity injection

Timeline

• Start date: 2025-07-01
• Primary completion: 2026-12-01
• Completion: 2027-05-01
• First posted: 2025-07-29
• Last updated: 2025-07-29

Locations

1 site across 1 country: China